Bevacizumab active in HIV-linked Kaposi's sarcoma

Bevacizumab active in HIV-Linked kaposi's sarcoma
For patients with HIV-associated Kaposi's sarcoma, bevacizumab is tolerated and induces a response in some patients, according to a study published online March 19 in the Journal of Clinical Oncology.

(HealthDay) -- For patients with HIV-associated Kaposi's sarcoma (HIV-KS), bevacizumab is tolerated and induces a response in some patients, according to a study published online March 19 in the Journal of Clinical Oncology.

Thomas S. Uldrick, M.D., from the in Bethesda, Md., and colleagues assessed the tolerability and efficacy of in 17 patients with HIV-KS that progressed or did not regress during highly-active antiretroviral therapy. Bevacizumab was administered intravenously to eligible patients with HIV-KS on days one and eight and every three weeks thereafter.

The researchers note that the median number of bevacizumab cycles was 10, during a median follow-up of 8.3 months. Of the 16 patients eligible for assessment, three had a complete response, two had a partial response, nine had stable disease, and two had disease progression, for an overall response rate (complete and partial response) of 31 percent. Of the five responders, four had received previous chemotherapy for KS. Grade 3 to 4 adverse events at least possibly related to therapy included hypertension in seven patients, neutropenia in five, cellulitis in three, and headache in two.

"Overall, this study suggests that bevacizumab has utility in KS," the authors conclude.

One of the authors disclosed holding patents on certain anti-HIV drugs. Bevacizumab for the study was provided by Genentech.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

2 hours ago

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

6 hours ago

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

Immunotherapy set to revolutionise cancer treatment

7 hours ago

Immunotherapy is set to revolutionise the treatment of cancer, according to ESMO President Professor Rolf A. Stahel. His comments come as the ESMO Symposium on Immuno-Oncology 2014 is about to open in Geneva, Switzerland ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.